Coultas DB, Zumwalt RE, Black WC, Sobonya RE: The epidemiology of interstitial lung diseases.
Am J Respir Crit Care Med 1994, 150:967–972.
Article
CAS
PubMed
Google Scholar
Raghu G, Nyberg F, Morgan G: The epidemiology of interstitial lung disease and its association with lung cancer.
Br J Cancer 2004,91(Suppl 2):S3–10.
Article
PubMed
PubMed Central
Google Scholar
American Thoracic Society (ATS) and the European Respiratory Society (ERS): Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement.
Am J Respir Crit Care Med 2000, 161:646–664.
Article
Google Scholar
British Thoracic Society recommendations: The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults.
Thorax 1999,54(Suppl 1):S1–30.
Google Scholar
Wilson JW, du Bois RM, King TE Jr: Challenges in pulmonary fibrosis: 8--The need for an international registry for idiopathic pulmonary fibrosis.
Thorax 2008, 63:285–287.
Article
CAS
PubMed
Google Scholar
Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, et al.: The clinical course of patients with idiopathic pulmonary fibrosis.
Ann Intern Med 2005, 142:963–967.
Article
PubMed
Google Scholar
Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ: Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease.
Lancet 1998, 351:24–27.
Article
CAS
PubMed
Google Scholar
Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR, et al.: Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med 2009, 179:717–723.
Article
CAS
PubMed
Google Scholar
Fung ET, Wright GL Jr, Dalmasso EA: Proteomic strategies for biomarker identification: progress and challenges.
Curr Opin Mol Ther 2000, 2:643–650.
CAS
PubMed
Google Scholar
Wikipedia: Biomarker. 22–5-2009. 23–5-2009
Sackett DL, Haynes RB: Evidence base of clinical diagnosis: The architecture of diagnostic research.
BMJ 2002, 324:539–541.
Article
CAS
PubMed
PubMed Central
Google Scholar
Greene KE, King TE Jr, Kuroki Y, Bucher-Bartelson B, Hunninghake GW, Newman LS, et al.: Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis.
Eur Respir J 2002, 19:439–446.
Article
CAS
PubMed
Google Scholar
Takahashi H, Fujishima TA, Koba H, Murakami S, Kurokawa K, Shibuya Y, et al.: Serum Surfactant Proteins A and D as Prognostic Factors in Idiopathic Pulmonary Fibrosis and Their Relationship to Disease Extent.
Am J Respir Crit Care Med 2000, 162:1109–1114.
Article
CAS
PubMed
Google Scholar
Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, et al.: Serum Surfactant Protein-A Is a Strong Predictor of Early Mortality in Idiopathic Pulmonary Fibrosis.
Chest 2009, 135:1557–1563.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M: New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6.
Chest 1989, 96:68–73.
Article
CAS
PubMed
Google Scholar
Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, Verstraeten AA, Livingston PO, Hilgers J, et al.: Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients.
Int J Cancer 2001, 93:97–106.
Article
CAS
PubMed
Google Scholar
Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M: Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer.
Am J Respir Crit Care Med 2000, 161:589–594.
Article
CAS
PubMed
Google Scholar
Hiraga Y, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, et al.: Immunoreactive MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer.
Oncology 1998, 55:307–319.
Article
CAS
PubMed
Google Scholar
Inoue Y, Nishimura K, Shiode M, Akutsu H, Hamada H, Fujioka S, et al.: Evaluation of serum KL-6 levels in patients with pulmonary tuberculosis.
Tuber Lung Dis 1995, 76:230–233.
Article
CAS
PubMed
Google Scholar
Yokoyama A, Kohno N, Hamada H, Sakatani M, Ueda E, Kondo K, et al.: Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med 1998, 158:1680–1684.
Article
CAS
PubMed
Google Scholar
Janssen R, Grutters JC, Sato H, van Velzen-Blad H, Zanen P, Kohno N, et al.: Analysis of KL-6 and SP-D as disease markers in bird fancier's lung.
Sarcoidosis Vasc Diffuse Lung Dis 2005, 22:51–57.
PubMed
Google Scholar
Nakashima T, Yokoyama A, Ohnishi H, Hamada H, Ishikawa N, Haruta Y, et al.: Circulating KL-6/MUC1 as an independent predictor for disseminated intravascular coagulation in acute respiratory distress syndrome.
J Intern Med 2008, 263:432–439.
Article
CAS
PubMed
Google Scholar
Kohno N, Yokoyama A, Kondo K: KL-6 as a serum marker for amiodarone-induced pulmonary toxicity.
Intern Med 2000, 39:1004–1005.
Article
CAS
PubMed
Google Scholar
Cobben NA, Drent M, Schols AM, Lamers RJ, Wouters EF, Van Dieijen-Visser MP: Serum lactate dehydrogenase and its isoenzyme pattern in ex-coalminers.
Respir Med 1997, 91:616–623.
Article
CAS
PubMed
Google Scholar
Drent M, Cobben NA, Henderson RF, Wouters EF, van Dieijen-Visser M: Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation.
Eur Respir J 1996, 9:1736–1742.
Article
CAS
PubMed
Google Scholar
Drent M, Cobben NA, Van Dieijen-Visser MP, Braat SH, Wouters EF: Serum lactate dehydrogenase activity: indicator of the development of pneumonitis induced by amiodarone.
Eur Heart J 1998, 19:969–970.
Article
CAS
PubMed
Google Scholar
Matusiewicz SP, Williamson IJ, Sime PJ, Brown PH, Wenham PR, Crompton GK, et al.: Plasma lactate dehydrogenase: a marker of disease activity in cryptogenic fibrosing alveolitis and extrinsic allergic alveolitis?
Eur Respir J 1993, 6:1282–1286.
CAS
PubMed
Google Scholar
van Krugten M, Cobben NA, Lamers RJ, Van Dieijen-Visser MP, Wagenaar SS, Wouters EF, et al.: Serum LDH: a marker of disease activity and its response to therapy in idiopathic pulmonary fibrosis.
Neth J Med 1996, 48:220–223.
Article
CAS
PubMed
Google Scholar
Schutyser E, Richmond A, Van DJ: Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes.
J Leukoc Biol 2005, 78:14–26.
Article
CAS
PubMed
PubMed Central
Google Scholar
Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, et al.: A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18.
Am J Respir Crit Care Med 2006, 173:781–792.
Article
CAS
PubMed
Google Scholar
Prasse A, Pechkovsky DV, Toews GB, Schafer M, Eggeling S, Ludwig C, et al.: CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis.
Arthritis Rheum 2007, 56:1685–1693.
Article
CAS
PubMed
Google Scholar
Thomeer MJ, Vansteenkiste J, Verbeken EK, Demedts M: Interstitial lung diseases: characteristics at diagnosis and mortality risk assessment.
Respir Med 2004, 98:567–573.
Article
PubMed
Google Scholar
Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al.: High-dose acetylcysteine in idiopathic pulmonary fibrosis.
N Engl J Med 2005, 353:2229–2242.
Article
CAS
PubMed
Google Scholar
Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, et al.: A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.
N Engl J Med 2004, 350:125–133.
Article
CAS
PubMed
Google Scholar
Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, et al.: Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia.
Am J Respir Crit Care Med 2003, 168:543–548.
Article
PubMed
Google Scholar
Erbes R, Schaberg T, Loddenkemper R: Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome?
Chest 1997, 111:51–57.
Article
CAS
PubMed
Google Scholar
Jezek V, Fucik J, Michaljanic A, Jezkova L: The prognostic significance of functional tests in cryptogenic fibrosing alveolitis.
Bull Eur Physiopathol Respir 1980, 16:711–720.
CAS
PubMed
Google Scholar
Schwartz DA, Helmers RA, Galvin JR, Van Fossen DS, Frees KL, Dayton CS, et al.: Determinants of survival in idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med 1994, 149:450–454.
Article
CAS
PubMed
Google Scholar
Rudd RM, Haslam PL, Turner-Warwick M: Cryptogenic fibrosing alveolitis: Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis.
Am Rev Respir Dis 1981, 124:1–8.
CAS
PubMed
Google Scholar
Mapel DW, Hunt WC, Utton R, Baumgartner KB, Samet JM, Coultas DB: Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts.
Thorax 1998, 53:469–476.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hanson D, Winterbauer RH, Kirtland S, Wu R: Changes in pulmonary function test: results after 1 year of therapy as predictors of survival in patients with pulmonary fibrosis.
Chest 1995, 108:305–310.
Article
CAS
PubMed
Google Scholar
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al.: Standardisation of spirometry.
Eur Respir J 2005, 26:319–338.
Article
CAS
PubMed
Google Scholar
Miller A, Elliott JC, Thornton JC, Warshaw R, Geiger M, Anderson H: Comparison of spirometry performed on the same subjects by two teams using similar instruments: an investigation of variability in prevalence of impairment.
Environ Res 1980, 21:229–234.
Article
CAS
PubMed
Google Scholar
Tukiainen P, Taskinen E, Holsti P, Korhola O, Valle M: Prognosis of cryptogenic fibrosing alveolitis.
Thorax 1983, 38:349–355.
Article
CAS
PubMed
PubMed Central
Google Scholar
Schwartz DA, Van Fossen D, Davis C, Helmers RA, Dayton CS, Burmeister L, et al.: Determinants of progression in idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med 1994, 149:444–449.
Article
CAS
PubMed
Google Scholar
Schwartz DA, Van Fossen D, Davis C, Helmers RA, Dayton CS, Burmeister L, et al.: Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the lung study group.
Am J Respir Crit Care Med 1998, 158:220–225.
Article
Google Scholar
Raghu G, DePaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, et al.: Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective, double-blind, randomized, placebo-controlled trial.
Am Rev Respir Dis 1991, 144:291–296.
Article
CAS
PubMed
Google Scholar
Raghu G, Craig JW, Lockhart D, Mageto Y: Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Results of a prospective, open-label phase II study.
Am J Respir Crit Care Med 1999, 159:1061–1069.
Article
CAS
PubMed
Google Scholar
Zanen P, van der LL, van der MT, van den Bosch JM: Reference values for alveolar membrane diffusion capacity and pulmonary capillary blood volume.
Eur Respir J 2001, 18:764–769.
Article
CAS
PubMed
Google Scholar
Aguilaniu B, Maitre J, Glenet S, Gegout-Petit A, Guenard H: European reference equations for CO and NO lung transfer.
Eur Respir J 2008, 31:1091–1097.
Article
CAS
PubMed
Google Scholar
O'Donnell D: Physiology of interstitial lung disease. In Interstitial lung disease. Edited by: Schwarz MI, King TE Jr. Hamilton, ON, Canada: Decker Inc; 1998:51–70.
Google Scholar
du Bois RM: Strategies for treating idiopathic pulmonary fibrosis.
Nat Rev Drug Discov 2010, 9:129–140.
Article
CAS
PubMed
Google Scholar
King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al.: Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.
Lancet 2009, 374:222–228.
Article
CAS
PubMed
Google Scholar
Fleischmann R: Primer: establishing a clinical trial unit - regulations and infrastructure.
Nat Clin Pract Rheumatol 2007, 3:234–239.
Article
PubMed
Google Scholar
Swigris JJ, Wamboldt FS, Behr J, du Bois RM, King TE, Raghu G, et al.: The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.
Thorax 2010, 65:173–177.
Article
PubMed
Google Scholar
Holland AE, Hill CJ, Conron M, Munro P, McDonald CF: Small changes in six-minute walk distance are important in diffuse parenchymal lung disease.
Respir Med 2009, 103:1430–1435.
Article
PubMed
Google Scholar
Lettieri CJ, Nathan SD, Browning RF, Barnett SD, Ahmad S, Shorr AF: The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis.
Respir Med 2006, 100:1734–1741.
Article
PubMed
Google Scholar
Caminati A, Bianchi A, Cassandro R, Mirenda MR, Harari S: Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis.
Respir Med 2009, 103:117–123.
Article
PubMed
Google Scholar
Hallstrand TS, Boitano LJ, Johnson WC, Spada CA, Hayes JG, Raghu G: The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis.
Eur Respir J 2005, 25:96–103.
Article
CAS
PubMed
Google Scholar
Eaton T, Young P, Milne D, Wells AU: Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia.
Am J Respir Crit Care Med 2005, 171:1150–1157.
Article
PubMed
Google Scholar
Lederer DJ, Arcasoy SM, Wilt JS, D'Ovidio F, Sonett JR, Kawut SM: Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med 2006, 174:659–664.
Article
PubMed
PubMed Central
Google Scholar
du Bois RM, Albera C, Costabel U, Bradford WZ, Kartashov A, Noble PW, Szwarcberg J, Thomeer M, Valeyre D, Weycker D, King TE: 6 minute walk test distance is a reliable, valid and responsive outcome measure that predicts mortality in patients with IPF.
Am J Respir Crit Care Med 2010, 181:A1103.
Google Scholar
Wells AU, Hansell DM, Rubens MB, Cullinan P, Black CM, du Bois RM: The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis.
Am Rev Respir Dis 1993, 148:1076–1082.
Article
CAS
PubMed
Google Scholar
Leung AN, Miller RR, Muller NL: Parenchymal opacification in chronic infiltrative lung diseases: CT-pathologic correlation.
Radiology 1993, 188:209–214.
Article
CAS
PubMed
Google Scholar
Lee JS, Im JG, Ahn JM, Kim YM, Han MC: Fibrosing alveolitis: prognostic implication of ground-glass attenuation at high-resolution CT.
Radiology 1992, 184:451–454.
Article
CAS
PubMed
Google Scholar
Remy-Jardin M, Giraud F, Remy J, Copin MC, Gosselin B, Duhamel A: Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation.
Radiology 1993, 189:693–698.
Article
CAS
PubMed
Google Scholar
Hansell DM, Wells AU: CT evaluation of fibrosing alveolitis--applications and insights.
J Thorac Imaging 1996, 11:231–249.
Article
CAS
PubMed
Google Scholar
Wells AU, Hansell DM, Corrin B, Harrison NK, Goldstraw P, Black CM, et al.: High resolution computed tomography as a predictor of lung histology in systemic sclerosis.
Thorax 1992, 47:738–742.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gay SE, Kazerooni EA, Toews GB, Lynch JP III, Gross BH, Cascade PN, et al.: Idiopathic pulmonary fibrosis: predicting response to therapy and survival.
Am J Respir Crit Care Med 1998, 157:1063–1072.
Article
CAS
PubMed
Google Scholar
Mouratidis B, Lising J, Nogrady S, Hurwitz M: Increased pertechnegas lung clearance in interstitial lung disease.
Clin Nucl Med 1999, 24:105–108.
Article
CAS
PubMed
Google Scholar
Barrowcliffe MP, Jones JG: Solute permeability of the alveolar capillary barrier.
Thorax 1987, 42:1–10.
Article
CAS
PubMed
PubMed Central
Google Scholar
Barrowcliffe MP, Jones JG: Pulmonary clearance of
99m
Tc-DTPA in the diagnosis and evolution of increased permeability pulmonary oedema.
Anaesth Intensive Care 1989, 17:422–432.
CAS
PubMed
Google Scholar
Kon OM, Daniil Z, Black CM, du Bois RM: Clearance of inhaled technetium-99m-DTPA as a clinical index of pulmonary vascular disease in systemic sclerosis.
Eur Respir J 1999, 13:133–136.
Article
CAS
PubMed
Google Scholar
Thomeer MJ, Dehaes B, Mortelmans L, Demedts M: Pertechnegas lung clearance in different forms of interstitial lung disease.
Eur Respir J 2002, 19:31–36.
Article
CAS
PubMed
Google Scholar
Keijsers RG, Verzijlbergen FJ, Oyen WJ, van den Bosch JM, Ruven HJ, van Velzen-Blad H, et al.: 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis.
Eur J Nucl Med Mol Imaging 2009, 36:1131–1137.
Article
CAS
PubMed
Google Scholar
Langah R, Spicer K, Gebregziabher M, Gordon L: Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis.
J Nucl Cardiol 2009, 16:801–810.
Article
PubMed
Google Scholar
Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC: Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis.
Chest 2007, 132:1949–1953.
Article
PubMed
Google Scholar
Ryu JH, Daniels CE, Hartman TE, Yi ES: Diagnosis of interstitial lung diseases.
Mayo Clin Proc 2007, 82:976–986.
Article
PubMed
Google Scholar